Analysts Anticipate Alpine Immune Sciences Inc (ALPN) Will Post Earnings of -$0.62 Per Share

Wall Street analysts expect Alpine Immune Sciences Inc (NASDAQ:ALPN) to report ($0.62) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Alpine Immune Sciences’ earnings, with the lowest EPS estimate coming in at ($0.80) and the highest estimate coming in at ($0.48). Alpine Immune Sciences reported earnings of ($0.38) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 63.2%. The firm is scheduled to announce its next quarterly earnings results on Monday, May 13th.

On average, analysts expect that Alpine Immune Sciences will report full year earnings of ($2.71) per share for the current financial year, with EPS estimates ranging from ($3.68) to ($2.10). For the next financial year, analysts anticipate that the company will post earnings of ($2.19) per share, with EPS estimates ranging from ($2.45) to ($1.84). Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow Alpine Immune Sciences.

Alpine Immune Sciences (NASDAQ:ALPN) last announced its earnings results on Monday, March 18th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.80).

A number of equities analysts have recently weighed in on ALPN shares. Zacks Investment Research raised Alpine Immune Sciences from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a research report on Thursday, January 24th. Oppenheimer set a $13.00 price target on Alpine Immune Sciences and gave the company a “buy” rating in a research report on Tuesday, March 19th. ValuEngine raised Alpine Immune Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, March 5th. Finally, reissued a “buy” rating and issued a $13.00 price target on shares of Alpine Immune Sciences in a research report on Tuesday, February 12th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Alpine Immune Sciences currently has an average rating of “Buy” and a consensus target price of $12.07.

ALPN stock traded down $0.14 during trading on Tuesday, hitting $6.29. The company had a trading volume of 190 shares, compared to its average volume of 11,904. Alpine Immune Sciences has a one year low of $3.66 and a one year high of $10.57. The stock has a market capitalization of $87.12 million, a PE ratio of -2.39 and a beta of 2.06. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.59 and a quick ratio of 6.59.

In other news, major shareholder Tiger Management L.L.C. sold 25,000 shares of the business’s stock in a transaction on Friday, February 8th. The stock was sold at an average price of $5.85, for a total value of $146,250.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 69.00% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of ALPN. Vanguard Group Inc. increased its position in Alpine Immune Sciences by 5.2% in the third quarter. Vanguard Group Inc. now owns 227,834 shares of the biotechnology company’s stock worth $1,442,000 after buying an additional 11,200 shares in the last quarter. Vanguard Group Inc boosted its stake in shares of Alpine Immune Sciences by 5.2% in the third quarter. Vanguard Group Inc now owns 227,834 shares of the biotechnology company’s stock worth $1,442,000 after acquiring an additional 11,200 shares during the period. Hikari Power Ltd bought a new position in shares of Alpine Immune Sciences in the fourth quarter worth about $453,000. Victory Capital Management Inc. boosted its stake in shares of Alpine Immune Sciences by 109.0% in the fourth quarter. Victory Capital Management Inc. now owns 136,072 shares of the biotechnology company’s stock worth $501,000 after acquiring an additional 70,980 shares during the period. Finally, Raymond James & Associates bought a new position in shares of Alpine Immune Sciences in the first quarter worth about $94,000. Institutional investors and hedge funds own 53.79% of the company’s stock.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.

Featured Story: How liquidity affects the bid-ask spread

Get a free copy of the Zacks research report on Alpine Immune Sciences (ALPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply